APOE C112R

This study used AlphaFold2 structure prediction to examine APOE4 carrying the C112R mutation, a rare variant associated with Alzheimer's disease that has not been observed in population databases (gnomAD). The protein structure achieved a moderate average confidence score (pLDDT of 71.8), indicating that while some regions are well-predicted, others may be intrinsically disordered or flexible. This confidence level is typical for APOE, which contains both structured lipid-binding domains and flexible regions that adapt to different binding partners. APOE4 is already known as the most significant genetic risk factor for Alzheimer's disease, impairing the brain's ability to clear amyloid-beta plaques, disrupting neuronal lipid and energy metabolism, and promoting harmful inflammation [1][2][3]. Recent large-scale studies demonstrate that APOE ε4 and ε3 variants collectively account for 72-93% of Alzheimer's cases, emphasizing APOE's dominant role in disease burden [1]. The C112R mutation replaces a cysteine at position 112 with arginine, potentially altering the protein's structure in the receptor-binding domain. Since cysteine can form stabilizing disulfide bonds while arginine is a charged residue, this substitution could affect how APOE4 folds, binds to receptors, or interacts with lipids—all critical functions for maintaining brain health. The absence of this variant in population databases combined with its ClinVar association classification suggests it may represent a rare pathogenic or risk-enhancing mutation. The structural impact remains speculative given the moderate confidence scores in the prediction, but the C112R change occurs in a functionally important region where APOE interacts with cell surface receptors. APOE4 already has reduced structural stability compared to protective APOE2 or neutral APOE3 variants, and additional destabilizing mutations like C112R could further impair its ability to transport cholesterol and clear toxic proteins from the brain [2][3]. The clinical significance of targeting APOE variants is increasingly recognized, with researchers emphasizing that interventions addressing APOE function—through gene therapy, small molecules that stabilize the protein, or drugs targeting downstream pathways—could prevent the majority of Alzheimer's cases [1][3]. Studies show that even high-risk APOE4 carriers benefit from modifiable lifestyle factors like cholesterol management and social engagement, though direct APOE-targeted therapies remain limited [3]. The interaction between APOE4 and other genetic factors, such as PLCG2 protective variants that can delay disease onset in APOE4 carriers, highlights the complexity of Alzheimer's genetic architecture [4].